Pacer Advisors Inc. Has $1.62 Million Holdings in Repligen Co. (NASDAQ:RGEN)

Pacer Advisors Inc. raised its stake in Repligen Co. (NASDAQ:RGEN) by 16.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,862 shares of the biotechnology company’s stock after acquiring an additional 1,808 shares during the quarter. Pacer Advisors Inc.’s holdings in Repligen were worth $1,621,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Repligen by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after acquiring an additional 21,719 shares in the last quarter. Brown Capital Management LLC raised its stake in shares of Repligen by 5.8% during the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock worth $274,207,000 after buying an additional 83,416 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after buying an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC raised its stake in shares of Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after buying an additional 121,305 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several recent research reports. UBS Group reduced their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Guggenheim started coverage on Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating on the stock. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and reduced their price target for the stock from $180.00 to $155.00 in a research report on Wednesday, June 26th. Finally, Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

Shares of Repligen stock opened at $147.18 on Friday. The company has a market capitalization of $8.22 billion, a PE ratio of 588.72, a PEG ratio of 4.16 and a beta of 0.94. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $148.35 and its 200 day simple moving average is $154.04.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.53 EPS. On average, research analysts predict that Repligen Co. will post 1.45 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.